Ken Griffin Xeris Biopharma Holdings, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$2.06 - $2.96 $1,442 - $2,072	700 Added 1.56%	45,700 $130,000
Q2 2024 Aug 14, 2024	SELL	$1.7 - $2.45 $60,180 - $86,730	-35,400 Reduced 44.03%	45,000 $101,000
Q1 2024 May 15, 2024	BUY	$2.04 - $3.22 $33,864 - $53,452	16,600 Added 26.02%	80,400 $177,000
Q4 2023 Feb 14, 2024	BUY	$1.47 - $2.36 $34,545 - $55,460	23,500 Added 58.31%	63,800 $149,000
Q3 2023 Nov 14, 2023	SELL	$1.8 - $2.69 $18,720 - $27,976	-10,400 Reduced 20.51%	40,300 $74,000
Q2 2023 Aug 14, 2023	BUY	$1.82 - $2.98 $34,398 - $56,322	18,900 Added 59.43%	50,700 $132,000
Q1 2023 May 15, 2023	SELL	$1.03 - $1.63 $33,578 - $53,138	-32,600 Reduced 50.62%	31,800 $51,000
Q4 2022 Feb 14, 2023	BUY	$1.14 - $1.65 $23,711 - $34,320	20,800 Added 47.71%	64,400 $85,000
Q3 2022 Nov 14, 2022	SELL	$1.37 - $1.93 $3,699 - $5,211	-2,700 Reduced 5.83%	43,600 $68,000

141

59.9M

148K

45.7K

Ticker XERS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,956,992
Market Cap $394M
Description
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.